ASTRAZEN - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.8
| Stock Code | ASTRAZEN | Market Cap | 21,556 Cr. | Current Price | 8,609 ₹ | High / Low | 10,691 ₹ |
| Stock P/E | 93.2 | Book Value | 320 ₹ | Dividend Yield | 0.37 % | ROCE | 33.4 % |
| ROE | 23.6 % | Face Value | 2.00 ₹ | DMA 50 | 8,691 ₹ | DMA 200 | 8,637 ₹ |
| Chg in FII Hold | -0.03 % | Chg in DII Hold | 0.29 % | PAT Qtr | 58.1 Cr. | PAT Prev Qtr | 56.1 Cr. |
| RSI | 55.8 | MACD | -29.9 | Volume | 6,028 | Avg Vol 1Wk | 4,846 |
| Low price | 6,502 ₹ | High price | 10,691 ₹ | PEG Ratio | 2.16 | Debt to equity | 0.04 |
| 52w Index | 50.3 % | Qtr Profit Var | 51.3 % | EPS | 79.7 ₹ | Industry PE | 29.1 |
📊 Analysis: ASTRAZEN is showing moderate intraday potential. Current price (₹8,609) is tightly aligned with both 50 DMA (₹8,691) and 200 DMA (₹8,637), indicating consolidation. RSI at 55.8 suggests neutral momentum, while MACD (-29.9) reflects mild bearishness. Volume (6,028) is above weekly average (4,846), hinting at active participation.
💹 Optimal Buy Price: ₹8,580 – ₹8,620 (near support zone).
🎯 Profit-Taking Levels: ₹8,720 – ₹8,780 (short-term resistance).
🛡️ Stop-Loss: ₹8,520 (below intraday support).
⏱️ Exit Strategy if Already Holding: Exit if price fails to sustain above ₹8,600 with weakening momentum or if RSI dips below 50 intraday. If momentum strengthens with volume, consider partial profit booking near ₹8,750.
Positive
- Strong ROCE (33.4%) and ROE (23.6%) highlight efficient capital use.
- Low debt-to-equity ratio (0.04) ensures financial stability.
- Quarterly profit growth (51.3%) indicates improving fundamentals.
- Volume higher than average shows active intraday interest.
Limitation
- High P/E (93.2) compared to industry average (29.1) makes valuation expensive.
- Dividend yield is low (0.37%), limiting passive returns.
- MACD negative, showing weak momentum.
Company Negative News
- Minor decline in FII holding (-0.03%) suggests reduced foreign investor confidence.
Company Positive News
- Increase in DII holding (+0.29%) shows domestic institutional support.
- Consistent PAT growth (₹58.1 Cr vs ₹56.1 Cr previous quarter).
Industry
- Pharma sector trading at lower industry P/E (29.1), making ASTRAZEN relatively overvalued.
- Sector remains defensive with steady demand, supporting intraday volatility opportunities.
Conclusion
⚖️ ASTRAZEN is a moderately good candidate for intraday trading today. Strong fundamentals support stability, but high valuation and weak MACD limit upside momentum. Best approach is cautious entry near ₹8,600 with tight stop-loss and quick profit booking around ₹8,750.